Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

BACKGROUND: Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. METHODS: Patients with primary triple negative breast cancer ≥2 cm received doxor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Di Cosimo, Serena, La Verde, Nicla, Moretti, Anna, Cazzaniga, Marina Elena, Generali, Daniele, Bianchi, Giulia Valeria, Mariani, Luigi, Torri, Valter, Crippa, Flavio, Paolini, Biagio, Scaperrotta, Gianfranco, De Santis, Maria Carmen, Di Nicola, Massimo, Apolone, Giovanni, Gulino, Alessandro, Tripodo, Claudio, Colombo, Mario Paolo, Folli, Secondo, de Braud, Filippo
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6685628/
https://ncbi.nlm.nih.gov/pubmed/31390375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0220644
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados